Patient Experiences with Pharmacogenetic Testing in a Primary Care Setting

References

• Shastry BS . Pharmacogenetics and the concept of individualized medicine . Pharmacogenomics J.6 ( 1 ), 16 – 21 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Miguel A , AzevedoLF , AraujoMet al. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis . Pharmacoepidemiol. Drug Saf.21 ( 11 ), 1139 – 1154 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Burton MM , HopeC , MurrayMDet al. The cost of adverse drug events in ambulatory care . AMIA Annu. Symp. Proc.11 , 90 – 93 ( 2007 ).
   Google Scholar
• Hug BL , KeohaneC , SegerDLet al. The costs of adverse drug events in community hospitals . Jt Comm. J. Qual. Patient Saf.38 ( 3 ), 120 – 126 ( 2012 ).
   PubMedGoogle Scholar
• Gu Q , DillonCF , BurtVL . Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008 . NCHS Data Brief ( 42 ), 1 – 8 ( 2010 ).
   Google Scholar
• Trinidad SB , CoffinTB , FullertonSMet al. “Getting off the bus closer to your destination”: patients’ views about pharmacogenetic testing . Perm. J.19 ( 3 ), 21 – 27 ( 2015 ).
   PubMedGoogle Scholar
• Rogausch A , PrauseD , SchallenbergAet al. Patients’ and physicians’ perspectives on pharmacogenetic testing . Pharmacogenomics7 ( 1 ), 49 – 59 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Fargher EA , EddyC , NewmanWet al. Patients’ and healthcare professionals’ views on pharmacogenetic testing and its future delivery in the NHS . Pharmacogenomics8 ( 11 ), 1511 – 1519 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Haga SB , O’DanielJM , TindallGMet al. Survey of US public attitudes toward pharmacogenetic testing . Pharmacogenomics J.12 ( 3 ), 197 – 204 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Haga SB , TindallG , O’DanielJM . Public perspectives about pharmacogenetic testing and managing ancillary findings . Genet. Test. Mol. Biomarkers.16 ( 3 ), 193 – 197 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lanktree MB , ZaiG , VanderbeekLEet al. Positive perception of pharmacogenetic testing for psychotropic medications . Hum. Psychopharmacol.29 ( 3 ), 287 – 291 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Zhang SC , BruceC , HaydenMet al. Public perceptions of pharmacogenetics . Pediatrics133 ( 5 ), e1258 – e1267 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Society TR . Pharmacogenetics dialogue: findings from public workshops on personalised medicines held by the Royal Society’s Science in Society programme ( 2005 ). https://royalsociety.org .
   Google Scholar
• Haddy CA , WardHM , AngleyMTet al. Consumers’ views of pharmacogenetics – a qualitative study . Res. Social Adm. Pharm.6 ( 3 ), 221 – 231 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Almarsdottir AB , BjornsdottirI , TraulsenJM . A lay prescription for tailor-made drugs – focus group reflections on pharmacogenomics . Health Policy71 ( 2 ), 233 – 241 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Pharmacogenomics: social, ethical, and clinical dimensions . RothsteinMA ( Ed. ). John Wiley & Sons, Inc. , Hoboken, NJ, USA ( 2003 ).
   Google Scholar
• Patel HN , UrsanID , ZuegerPMet al. Stakeholder views on pharmacogenomic testing . Pharmacotherapy34 ( 2 ), 151 – 165 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Madadi P , JolyY , AvardDet al. Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: a pilot study of perceptions and benefits . Clin. Pharmacol. Ther.88 ( 6 ), 792 – 795 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Bloss CS , SchorkNJ , TopolEJ . Direct-to-consumer pharmacogenomic testing is associated with increased physician utilisation . J. Med. Genet.51 ( 2 ), 83 – 89 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Haga SB , Allen LapointeNM , ChoAet al. Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting . Pharmacogenomics15 ( 13 ), 1677 – 1686 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Horne R , WeinmanJ . Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness . J. Psychosom. Res.47 ( 6 ), 555 – 567 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Morisky DE , GreenLW , LevineDM . Concurrent and predictive validity of a self-reported measure of medication adherence . Med. Care24 ( 1 ), 67 – 74 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Cella D , HughesC , PetermanAet al. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire . Health Psychol.21 ( 6 ), 564 – 572 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Morisky DE , AngA , Krousel-WoodMet al. Predictive validity of a medication adherence measure in an outpatient setting . J. Clin. Hypertens.10 ( 5 ), 348 – 354 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Charland SL , AgatepBC , HerreraVet al. Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial . Pharmacogenomics J.14 ( 3 ), 272 – 280 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Li JH , JoySV , HagaSBet al. Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in primary care patients . J. Pers. Med.4 ( 2 ), 147 – 162 ( 2014 ).
   PubMedGoogle Scholar
• Payne K , FargherEA , RobertsSAet al. Valuing pharmacogenetic testing services: a comparison of patients’ and health care professionals’ preferences . Value Health14 ( 1 ), 121 – 134 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wagner Costalas J , ItzenM , MalickJet al. Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program’s experience . Am. J. Med. Genet. C Semin. Med. Genet.119C ( 1 ), 11 – 18 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Stoffel EM , FordB , MercadoRCet al. Sharing genetic test results in Lynch syndrome: communication with close and distant relatives . Clin. Gastroenterol. Hepatol.6 ( 3 ), 333 – 338 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lehmann LS , WeeksJC , KlarNet al. Disclosure of familial genetic information: perceptions of the duty to inform . Am. J. Med.109 ( 9 ), 705 – 711 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Plantinga L , NatowiczMR , KassNEet al. Disclosure, confidentiality, and families: experiences and attitudes of those with genetic versus nongenetic medical conditions . Am. J. Med. Genet. C Semin. Med. Genet.119C ( 1 ), 51 – 59 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Bevan JL , LynchJA , DubriwnyTNet al. Informed lay preferences for delivery of racially varied pharmacogenomics . Genet. Med.5 ( 5 ), 393 – 399 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Schildcrout JS , DennyJC , BowtonEet al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping . Clin. Pharmacol. Ther.92 ( 2 ), 235 – 242 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Carpenter JS , RosenmanMB , KniselyMRet al. Pharmacogenomically actionable medications in a safety net health care system . SAGE Open Med.4 , 2050312115624333 ( 2016 ).
   PubMedGoogle Scholar